skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Lenvatinib Mesylate (Code C48636)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Lenvatinib Mesylate

Definition: A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.

Display Name: Lenvatinib Mesylate

Label: Lenvatinib Mesylate

NCI Thesaurus Code: C48636 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2987642  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
4-[3-Chloro-4-(N'-cyclopropylureido)phenoxy]7-methoxyquinoline-6-carboxamide Mesylate
6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]- 7-methoxy-, methanesulfonate (1:1)
Lenvatinib Mesylate
Multi-Kinase Inhibitor E7080

External Source Codes: 
CAS Registry Number 857890-39-2 (see NLM ChemIDplus info)
FDA UNII Code 3J78384F61
PDQ Closed Trial Search ID 445461
PDQ Open Trial Search ID 445461 (check for NCI PDQ open clinical trial info)
PubMedID Primary Reference 18765537 (see PubMed Primary Reference info)
UMLS CUI C2987642

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C21H19ClN4O4.CH4O3S
code C48636
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name E7080
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom